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Abstract
A constellation of metabolic disorders, including obesity, dysregulated lipids, and elevations
in blood glucose levels, has been associated with cardiovascular disease and diabetes.
Analysis of data from recently published genome-wide association studies (GWAS) demon-
strated that reduced-function polymorphisms in the organic cation transporter, OCT1
(SLC22A1), are significantly associated with higher total cholesterol, low-density lipoprotein
(LDL) cholesterol, and triglyceride (TG) levels and an increased risk for type 2 diabetes mel-
litus, yet the mechanism linking OCT1 to these metabolic traits remains puzzling. Here, we
show that OCT1, widely characterized as a drug transporter, plays a key role in modulating
hepatic glucose and lipid metabolism, potentially by mediating thiamine (vitamin B1) uptake
and hence its levels in the liver. Deletion of Oct1 in mice resulted in reduced activity of thia-
mine-dependent enzymes, including pyruvate dehydrogenase (PDH), which disrupted the
hepatic glucose–fatty acid cycle and shifted the source of energy production from glucose to
fatty acids, leading to a reduction in glucose utilization, increased gluconeogenesis, and
altered lipid metabolism. In turn, these effects resulted in increased total body adiposity
and systemic levels of glucose and lipids. Importantly, wild-type mice on thiamine deficient
diets (TDs) exhibited impaired glucose metabolism that phenocopied Oct1 deficient mice.
Collectively, our study reveals a critical role of hepatic thiamine deficiency through OCT1
deficiency in promoting the metabolic inflexibility that leads to the pathogenesis of cardiome-
tabolic disease.
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Author summary
The liver is the major organ for glucose and lipid metabolism; impairment in liver energy
metabolism is often found in metabolic disorders. Traditionally, excesses in macronutri-
ents (fat and glucose) are linked to the development of metabolic disorders. Our study
provides evidence that imbalances in a micronutrient, vitamin B1 (thiamine), can serve as
an etiological cause of lipid and glucose disorders and implicates the organic cation trans-
porter, OCT1, in these disorders. OCT1 is a key determinant of thiamine levels in the
liver. In humans, reduced-function polymorphisms of OCT1 significantly associate with
high LDL cholesterol levels. Using Oct1 knockout mice, we show that reduced OCT1-
mediated thiamine uptake in the liver leads to reduced levels of TPP—the active metabo-
lite of thiamine—and decreased activity of key TPP-dependent enzymes. As a result, a
shift from glucose to fatty acid oxidation occurs, leading to imbalances in key metabolic
intermediates, alterations in metabolic flux pathways, and disruptions of various meta-
bolic regulatory mechanisms. The extensive characterization of Oct1 knockout mice pro-
vides evidence for the molecular mechanisms responsible for various metabolic traits
and indicates an important role for imbalances in micronutrients in cardiometabolic
disorders.
Introduction
Hepatic energy metabolism is a major determinant of systemic glucose and lipid levels as well
as total body adiposity, which in turn are key risk factors for cardiovascular and metabolic dis-
eases [1, 2]. Genome-wide association studies (GWAS) have provided a wealth of information
on the genes and pathways involved in hepatic energy metabolism, including apolipoprotein E
(APOE), proprotein convertase subtilisin/kexin type 9 (PCSK9), and low-density lipoprotein
receptor (LDLR) [3–5]. In follow-up studies in cells and in preclinical animal models, most of
these genes have been linked mechanistically to lipid metabolism [6]. In contrast, the mecha-
nisms responsible for the genome-wide–level significant association of SLC22A1 (encoding the
organic cation transporter, OCT1) with total and low-density lipoprotein (LDL) cholesterol
[3] remains unexplored.
In humans, the OCT1 gene is highly polymorphic. A number of reduced-function variants
with high prevalence in European populations have been characterized [7–9]. In particular,
40% of Caucasians carry one and 9% carry two reduced-function OCT1 variants [7, 8]. OCT1,
which is highly expressed in the liver, has been widely characterized as a drug uptake trans-
porter. Reduced-function polymorphisms of OCT1 have been associated with changes in the
pharmacokinetics and pharmacodynamics of several drugs, including the opiate receptor ago-
nist, morphine, and the anti-diabetic drug, metformin [10–12]. Recently, GWAS and fine
mapping analysis showed that OCT1 functional variants are associated with acylcarnitine lev-
els through efflux mechanism [13].
Previously, through metabolomic studies in Oct1-/- mice and in cells overexpressing human
OCT1, our laboratory identified thiamine, vitamin B1, as a major endogenous substrate for
OCT1, and Oct1 knockout mice were shown to exhibit hepatic thiamine deficiency [14].
Although systemic thiamine deficiency is well known to cause nerve damage and lead to beri-
beri and Wernicke-Korsakoff syndrome [15, 16], the pathophysiologic effects of thiamine defi-
ciency in the liver are not understood. Thiamine pyrophosphate (TPP), the active metabolite
of thiamine, is an essential cofactor for several metabolic enzymes, including pyruvate dehy-
drogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase (TK), which
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have fundamental roles in regulating cellular energy metabolism [15]. In particular, in 1963
Randle proposed that PDH acts as a key metabolic switch in the glucose–fatty acid cycle,
which underlies the metabolic disturbance of diabetes. Under the theory of substrate competi-
tion between glucose and fatty acids, an increase in fatty acid oxidation and a reduction in gly-
colytic flux result in a critical imbalance in energy metabolism in tissues. As noted by Randle,
regulation of PDH activity greatly influences selection of fuel source [17, 18]. Failure to flexibly
adjust the choice of fuel (e.g., fatty acids or glucose) for metabolic energy production has
recently been proposed to underlie metabolic inflexibility and lead to the pathogenesis associ-
ated with metabolic disorders [19]. Metabolic inflexibility and indeed metabolic syndrome
have been linked to an excess of macronutrients (e.g., carbohydrates or fat); however, the role
of micronutrients such as thiamine in metabolic syndrome has been largely ignored. Although
many reports have identified a high prevalence of thiamine deficiency in patients with diabetes
or obesity [20–23] and a beneficial effect of thiamine supplementation in these patient popula-
tions [24–26], the molecular mechanisms contributing to thiamine-associated metabolic dis-
turbance are unknown.
Here, we hypothesize that reduced OCT1 function or reduced dietary thiamine intake lead-
ing to decreases in hepatic thiamine levels modulates the activity of multiple enzymes and the
levels of key metabolites involved in glucose and lipid metabolism. These effects result in dysli-
pidemias, increases in circulating glucose levels, and peripheral adiposity. Through extensive
experiments in Oct1-/- mice, our data show that Oct1 deficiency results in substantial changes
in hepatic energy metabolism, i.e., reduction in glucose utilization, increased gluconeogenesis,
and alterations in lipid metabolism. Similarly, feeding wild-type mice a thiamine deficient diet
(TD) results in comparable effects on hepatic energy metabolism. Taken together, our studies
suggest that hepatic thiamine deficiency, through deletion of Oct1 in mice, results in the devel-
opment of metabolic inflexibility. Our studies provide a mechanistic explanation for the strik-
ing metabolic findings in large-scale human genetic studies, demonstrating that common
OCT1 reduced-function polymorphisms are associated with dyslipidemias, obesity, and
increased risk for type 2 diabetes.
Results
OCT1 reduced-function variants are strongly associated with human lipid
levels
The GWAS Catalog, database of Genotypes and Phenotypes (dbGAP) Association Results
Browser, and Genome-Wide Repository of Associations Between SNPs and Phenotypes
(GRASP) identified two major phenotypes (total cholesterol and LDL cholesterol levels) that
were associated with genetic variants in SLC22A1 (OCT1) (Fig 1 and S1A and S1B Fig). In par-
ticular, rs1564348 and rs11753995 were associated with LDL cholesterol (p = 2.8 × 10−21) and
total cholesterol (p = 1.8 × 10−23), respectively (Fig 1 and Table 1). Using HaploReg v4.1 to
obtain linkage disequilibrium information from 1000 Genomes Project, we noted that these
two SNPs are in linkage with the OCT1 with methinone420 deletion (420Del), a common
genetic variant in OCT1 that shows reduced uptake and altered kinetics of its substrates. Thus,
the results suggest that reduced OCT1 function is significantly associated with higher total
cholesterol and higher LDL levels. The GRASP database identified other phenotypes with sig-
nificant, but weaker, p-values, relevant to glucose traits and coronary artery disease. Recent
results from the UK Biobank cohort (http://geneatlas.roslin.ed.ac.uk/), available in the Gene
ATLAS database and from the Global Lipids Genetic Consortium, are also included in Table 1.
As shown, the reduced-function OCT1 nonsynonymous variants, OCT1-R61C, OCT1-G401S,
OCT1-420Del, and OCT1-G465R, were significantly associated with high total cholesterol,
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Fig 1. Manhattan plots and regional plots of the SLC22A1 locus associated with lipid levels. Manhattan plots for (A) LDL cholesterol levels and (B) total
cholesterol (−log10 P) in up to 188,577 individuals with European ancestries. The data are plotted using the results available from the Global Lipids Genetics
Consortium, http://csg.sph.umich.edu/abecasis/public/lipids2013/ [3]. Only the SNPs with p-value ranges from 0.05 to 1 × 10−25 are plotted in (A) and (B).
S1 Fig shows the Manhattan plots for all SNPs. APOE, PCSK9, and LDLR are among the genes previously known to associate with lipid levels, as highlighted
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LDL cholesterol, and/or TG levels in at least one study (Table 1). In addition, two of the mis-
sense OCT1 variants, OCT1-P341L and OCT1-V408M, which are associated with lower
SLC22A1 expression levels in several tissues [13, 27, 28], were also associated with higher cho-
lesterol levels in at least one study. The OCT1 nonsynonymous variants in Table 1, except
OCT1-P341L, are not in linkage disequilibrium (r2 < 0.1) with SNPs in lipoprotein(a) (LPA)
and lipoprotein(a) like 2 (LPAL2) genes (a known locus for plasma lipoprotein levels) [29–31]
(S1C Fig), indicating that OCT1 constitutes an independent locus for association with plasma
lipids, which was also recently shown in other studies [32, 33]. Notably, the effect size of the
OCT1 variants for associations with lipids traits are small; thus, larger sample sizes are needed
for genome-wide level significance (p< 5 × 10−8) (Table 1). In the Type 2 Diabetes Knowledge
Portal, weaker but significant associations (p< 0.05) between OCT1 reduced-function variants
and higher 2-hour glucose levels, higher fasting insulin levels, increased risk for type 2 diabetes,
increased risk for coronary artery disease, and higher BMI were cataloged (Table 1). We per-
formed burden test analysis using the data available in the portal. Interestingly, in the analysis,
in which we included possibly or probably deleterious missense or protein truncating variants
of OCT1, we observed strong associations of the reduced-function OCT1 variants with
increased body weight (p = 0.0002–0.0005, beta = 0.23–0.3). When we performed a similar
burden test analysis with type 2 diabetes, the significance was weaker and the results were only
significant when we included only protein truncating variants of OCT1 (p = 0.015, odds
ratio = 2.10).
Deletion of Oct1 altered hepatic and peripheral energy homeostasis
Consistent with our previous studies, deletion of Oct1 protected the mice from hepatic steato-
sis [14] (Fig 2A, S2A Fig). In this study, we observed that glycogen content was 3.3-fold greater
in livers from Oct1-/- mice compared to livers from Oct1+/+ mice after an overnight fast (Fig 2A
and S2B Fig). Consistent with these results, hepatic glucose levels were 5.9-fold higher
(p = 0.0006) in Oct1-/- mice compared to Oct1+/+ mice (S2C Fig). Significantly greater body
weights were observed for Oct1-/- mice compared to their wild-type counterparts, starting at
the age of 6 weeks (Fig 2B and S2D Fig). Body composition also differed, with dual-energy X-
ray absorptiometry (DEXA) scans showing a higher percent of body fat in Oct1-/- compared to
Oct1+/+ mice (p = 0.001) (Fig 2C). Consistent with the greater proportion of body fat, Oct1-/-
mice had greater epididymal fat pad weights and reduced liver weight compared to Oct1+/+
mice (p< 0.0001) (Fig 2D and S2E Fig).
To further assess the potential mechanism leading to increased weight gain in Oct1-/- mice,
we analyzed energy expenditure, food intake, and activity by the comprehensive laboratory
in (A) and (B). Over 100 loci were associated with lipids at p< 5 × 10−8, including SLC22A1, which is the top locus in chromosome 6. The regional plots of
the SLC22A1 locus for (C) LDL cholesterol levels and (D) total cholesterol. SNPs are plotted by position on chromosome 6 (hg19) against association with
meta-analysis of (C) LDL cholesterol levels and (D) total cholesterol in up to 188,577 individuals. The plots show that rs1564348 and rs11753995 (purple
circles) are the top signals for (C) LDL cholesterol (p = 2.8 × 10−21) and (D) total cholesterol (p = 1.8 × 10−23), respectively. Both SNPs have strong linkage
disequilibrium with the SLC22A1-420 deletion (rs202220802) (r2 = 0.78, D0 = 0.99) (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php). The
red arrow points to a nonsynonymous SNP, rs12208357 (SLC22A1-R61C), which is associated with (C) LDL cholesterol (p = 6.6 × 10−10) and with (D) total
cholesterol (p = 1.3 × 10−8). Blue arrows point to an intronic SNP in SLC22A1, rs662138, which is included in many genome-wide genotyping platforms and
also has strong linkage disequilibrium with the SLC22A1-420 deletion (rs202220802) (r2 = 0.78, D0 = 0.99). The associations of rs662138 with other traits are
shown in Table 1. Estimated recombination rates (cM/Mb) are plotted in a blue line to reflect the local linkage disequilibrium structure. The SNPs
surrounding the most significant SNP, (C) rs1564348 and (D) rs11753995, are color coded to reflect their linkage disequilibrium with other SNPs in the
locus, based on pairwise r2 values from the HapMap CEU data. Genes, the position of exons, and the direction of transcription from the UCSC Genome
Browser are noted. APOE, apolipoprotein E; CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; IGF2R, insulin
like growth factor 2 receptor; LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; LOC729603, non-coding RNA; PCSK9, proprotein
convertase subtilisin/kexin type 9; rs, reference single nucleotide polymorphisms (SNPs); SLC, Solute Carrier; TC, total cholesterol; UCSC, University of
California, Santa Cruz.
https://doi.org/10.1371/journal.pbio.2002907.g001
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animal monitoring system (CLAMS). Before placing the mice into the CLAMS, the body com-
position of all mice was measured by EchoMRI. As shown in Fig 2E, Oct1-/- mice had greater
fat and lower lean mass in comparison to Oct1+/+ mice (p< 0.0001). When normalized to total
body weight, Oct1-/- mice had significantly lower respiratory oxygen (O2) consumption and
energy expenditure (Fig 2F and 2G), indicating lower metabolic rates of Oct1-/- mice in com-
parison to Oct1+/+ mice. These data are consistent with the lower lean mass of the Oct1-/- mice
compared to Oct1+/+ mice, because lean mass contributes more to energy expenditure than
more inert tissue, such as adipose tissue [39, 40]. In fact, no differences in respiratory O2 con-
sumption or energy expenditure normalized to lean mass were observed between Oct1+/+ and
Fig 2. Oct1 deletion altered energy homeostasis in vivo. Beginning at 5 weeks, mice were treated with a thiamine control diet. (A) Representative images of
ORO and PAS staining of mouse livers (n = 3 per genotype); scale bars = 100 μm. Quantified hepatic triglyceride (n = 4 per genotype) and glycogen levels
(n = 10 per genotype) in mice fasted 16 hours overnight. (B) Body weight of mice from ages 4 to 14 weeks (n = 12–24 per genotype at each time point). (C)
Representative images for body composition measured by DEXA (n = 6 per genotype). Percent of total body fat and percent of fat in the region is indicated by
the green square (n = 6 per genotype). (D) Representative images and weights of epididymal fat pads (n = 14 per genotype). (E) Body composition of 12-week-
old mice measured by EchoMRI before CLAMS (n = 12 per genotype). (F) Respiratory O2 consumption normalized by total body weight for 96 hours and
calculated AUC (n = 12 per genotype). (G) Energy expenditure normalized by total body weight for 96 hours and calculated AUC (n = 12 per genotype). Data
shown are mean ± SEM. Data were analyzed by unpaired two-tailed Student t test; p< 0.05, p< 0.01, and p< 0.001. Underlying data are provided in S1
Data. AUC, area under the curve; CLAMS, comprehensive laboratory animal monitoring system; DEXA, dual-energy X-ray absorptiometry; Oct1, organic
cation transporter 1; ORO, Oil Red-O; O2, oxygen; PAS, Periodic-Acid Schiff’s; TG, triglyceride; VO2, oxygen consumption.
https://doi.org/10.1371/journal.pbio.2002907.g002
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Oct1-/- mice (S2F and S2G Fig). Thus, the differences in metabolic rate between Oct1+/+ and
Oct1-/- mice appear to be due to significant differences in body composition. Additionally, our
Oct1-/- mice had no difference in activity but had slightly lower food intake and respiratory
exchange ratio (RER) during the dark cycle compared to Oct1+/+ mice (S2H–S2J Fig). There
were no deleterious effects of Oct1 deficiency on hepatic function and, in fact, some of the liver
function tests improved in the Oct1 knockout mice in comparison to wild-type mice (S2K
Fig). There were no major differences in the expression levels of thiamine transporters
(Slc19a2 and Slc19a3) in the liver. In contrast, levels of organic cation transporter, Oct2, which
also transports thiamine, were increased, albeit the expression levels of Oct2 in the liver were
extremely low relative to Oct1 and Slc19a2 (S2L Fig). Collectively, our data suggest that Oct1
deletion had a significant effect on hepatic and peripheral energy homeostasis.
Deletion of Oct1 altered thiamine disposition and protected mice from
beriberi
We hypothesized that the systemic plasma levels of thiamine are higher in Oct1-/- mice as a
result of reduced hepatic extraction of dietary thiamine (Fig 3A). As expected, Oct1-/- mice had
Fig 3. Oct1 function modulated thiamine disposition in vivo and in vitro. (A) Scheme: deletion of Oct1 reduces hepatic uptake of
thiamine and increases plasma thiamine levels. (B) Plasma thiamine levels (n = 6 per genotype on a control diet; n = 7 per genotype on
a TD). (C) Survival curves for mice on TDs (n = 7 for Oct1+/+ mice and n = 9 for Oct1-/- mice). Animals were euthanized once the
humane end points (body condition score of 2 or less or 15% body weight loss) were reached during the treatment (Gehan-Breslow-
Wilcoxon test and log-rank test were used for analysis). (D) Representative graph of thiamine uptake in cells stably expressing EV,
hOCT1-Ref, hOCT1-420Del, and hOCT1-420Del+G465R; a total of 25 nM thiamine was included in the uptake buffer. Representative
graph of thiamine kinetics in cells expressing hOCT1-Ref and hOCT1-420Del; concentrations ranged from 25 nM to 2 mM; uptake
was performed for 4 minutes. n = 3 replicated wells; two separate experiments were performed for the in vitro studies. (E) The area
under the plasma concentration-time curve of thiamine. A single intraperitoneal injection of 2 mg/kg thiamine (with 4% 3H-thiamine)
was administered to four groups of mice (Oct1+/+ mice treated with control shRNA, n = 6; Oct1+/+ mice treated with Oct1 shRNA,
n = 6; Oct1-/- mice treated with control shRNA, n = 3 and Oct1-/- mice treated with Oct1 shRNA, n = 3) Data are normalized to Oct1+/+
mice treated with control shRNA. Data shown are mean ± SEM. Data were analyzed by unpaired two-tailed Student t test; p< 0.05,
p< 0.01, and p< 0.001. Underlying data are provided in S1 Data. AUC, area under the curve; EV, empty vector; hOCT1-Ref,
human OCT1 reference; hOCT1-420Del, human OCT1 with methinone420 deletion; hOCT1-420Del+G465R, human OCT1 with
mutation in glycine465-to-arginine in addition to 420Del; Oct1, organic cation transporter 1; shRNA, short hairpin RNA; TD, thiamine
deficient diet.
https://doi.org/10.1371/journal.pbio.2002907.g003
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significantly higher plasma levels of thiamine (Fig 3B and S3A Fig) compared to Oct1+/+ mice
on thiamine-controlled and thiamine-enriched diets. In addition, Oct1 deletion preserved
plasma thiamine levels in mice on TDs (Fig 3B). Thiamine deficiency is associated with life-
threatening diseases, such as beriberi and Wernicke-Korsakoff syndrome [15, 41]. We hypoth-
esized that preserved circulating thiamine levels would delay the development of severe thia-
mine deficiency syndromes and increase the rate of survival when mice were challenged with a
TD. As shown in Fig 3C, there was a significant improvement in the overall survival of Oct1-/-
mice (p = 0.012, Gehan-Breslow-Wilcoxon test; p = 0.018, log-rank test) compared to Oct1+/+
mice. Modulation of Oct1 expression levels provides a means of studying the effect of hepatic
thiamine levels per se as opposed to systemic thiamine levels or thiamine levels in other tissues.
Manipulation of dietary thiamine may have additional effects, for example, in the central ner-
vous system. Notably, Liu and colleagues determined that reduced levels of thiamine in the sys-
temic circulation in mice resulted in neurological effects in the hypothalamus, with anorexia
and resultant reduction in peripheral adiposity [42].
In human populations, the OCT1 gene is highly polymorphic [7–9, 43]. Many loss-of-func-
tion polymorphisms of OCT1 have been characterized and found to affect hepatic uptake of
drugs, leading to altered treatment response [43]. Here, in the uptake studies, cells expressing
human OCT1 genetic variants (420Del or 420Del+G465R) had significantly reduced uptake of
thiamine compared to the reference allele (Fig 3D), although they have comparable levels of
OCT1 transcript (S3C Fig). In kinetic studies performed at 4 minutes, the maximum velocity
(Vmax) of thiamine in cells expressing human OCT1 with methinone420 deletion (hOCT1-
420Del) was 70% lower than in cells expressing the human OCT1 reference (hOCT1-Ref)
(1.80 ± 0.09 nmol/mg protein/minute versus 5.36 ± 0.30 nmol/mg protein/minute) (Fig 3D).
In contrast to humans, who express OCT1 primarily in the liver, mice express Oct1 in both the
liver and the kidney; therefore, deletion of Oct1 in the kidney could potentially affect systemic
levels of thiamine in mice. To address this limitation of the Oct1 knockout mice as a model for
humans, we used hydrodynamic tail vein injection of mouse Oct1 short hairpin RNA (shRNA)
lentiviral particle (or empty vector shRNA lentiviral particle as control) to specifically knock
down Oct1 in the liver in both Oct1+/+ and Oct1-/- mice. Following a single intraperitoneal
injection of 2 mg/kg thiamine (with 4% 3H-thiamine), we observed that the area under the
plasma concentration-time curve (AUC) of thiamine was significantly greater in wild-type
mice treated with Oct1 shRNA lentiviral particles compared to wild-type mice treated with
vector control shRNA lentiviral particles (Fig 3E). Although not significant, similar trends
were observed in the maximum concentration (Cmax) values (S3D Fig). Notably, the Oct1
shRNA did not affect Oct1 expression levels in the kidney (S3D Fig). Compared to wild-type
mice with Oct1 shRNA lentiviral particle knockdown, higher systemic levels of thiamine were
observed in Oct1-/- mice (Fig 3E), potentially reflecting an incomplete Oct1 knockdown (50%
liver Oct1 expression reduction, S3D Fig) or an additive effect of renal Oct1 deletion in Oct1-/-
mice. The data provide strong evidence that reduction of OCT1 expression in the liver alone
can result in increased systemic thiamine exposure. Although the liver plays a role in pre-sys-
temic thiamine metabolism, it should be noted that thiamine is metabolized in most tissues in
the body; therefore, other tissues, such as the intestine, may contribute to pre-systemic metab-
olism of the vitamin. Collectively, alterations in OCT1 function through genetic polymor-
phisms affect thiamine uptake and disposition.
Deletion of Oct1 disrupted hepatic glucose metabolism
Our previous studies indicated that Oct1 deletion resulted in reduced hepatic thiamine levels
and levels of TPP [14], the cofactor of PDH. It is shown that reduced TPP levels directly affect
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the activity of PDH [44, 45]. As PDH plays a key role in energy metabolism linking glycolysis
to the tricarboxylic acid (TCA) cycle and fatty acid metabolism [17], we hypothesized that the
activity of hepatic PDH was impaired in Oct1-/- mice. Because phosphorylation of PDH results
in inactive forms of the enzyme [46], we measured levels of phosphorylated PDH (at two phos-
phorylation sites, Ser232 and Ser300) and mRNA levels of pyruvate dehydrogenase kinase 4
(PDK4). Both phosphorylated PDHs and PDK4 transcripts were significantly higher in livers
from Oct1-/- mice (Fig 4A and S4A Fig). In addition, in Oct1-/- mice, glycogen synthase (GS),
and glucose transporter 2 (Glut2) were present at significantly higher levels (Fig 4A). Although
Fig 4. Deletion of Oct1 altered hepatic glucose metabolism. (A) Representative western blots of key proteins involved in energy metabolism in mouse
liver. Quantification of the western blots is shown in the right panel (n = 4–10 mice per genotype). (B) Hepatic glucose-6-phosphate levels (n = 4 per
genotype). (C) Western blot of GS-p641, GS, and loading control β-actin. Mice were fasted overnight for 16 hours for (A), (B), and (C). (D) GTT in mice
fasted for 5 hours, adjusted for baseline, and associated glucose AUC (n = 10 per genotype). (E) PTT in mice fasted for 16 hours, adjusted for baseline, and
associated glucose AUC (n = 6 per genotype). (F) ITT in mice fasted for 5 hours and associated glucose AUC (n = 6 per genotype). Data shown are
mean ± SEM. Data were analyzed by unpaired two-tailed Student t test; p< 0.05, p< 0.01, and p< 0.001. Underlying data are provided in S1 Data.
AMPK, AMP-activated protein kinase; AUC, area under the curve; Glut2, glucose transporter 2; GTT, glucose tolerance test; GS, glycogen synthase; GS-
p641, phospho-glycogen synthase at S641; ITT, insulin tolerance test; Oct1, organic cation transporter 1; pACC, phosphorylate acetyl-CoA carboxylase;
pAMPK, phosphorylate 5’ adenosine monophosphate-activated protein kinase; PDH, pyruvate dehydrogenase; PDH-p, phospho-pyruvate dehydrogenase;
PTT, pyruvate tolerance test; PYGL; glycogen phosphorylase.
https://doi.org/10.1371/journal.pbio.2002907.g004
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glycogen phosphorylase (PYGL), which plays a key role in breakdown of hepatic glycogen, was
also expressed at higher levels, the ratio of GS to PYGL was significantly higher in livers from
Oct1-/- mice (Fig 4A and S4B and S4C Fig). These data suggest that Oct1-/- mice had higher rates
of glycogen synthesis, which could explain the higher hepatic glycogen content in Oct1-/- mice.
Our data suggested that livers from Oct1-/- mice would have less activity of PDH, which in
turn would result in a lower rate of conversion of pyruvate to acetyl-CoA entering the TCA
cycle [47, 48] and thus an overall reduction in oxidative phosphorylation of glucose. We
hypothesized that the reduction of oxidative phosphorylation of glucose would increase the
accumulation of the intermediates of gluconeogenic substrates. These intermediates would
lead to increased gluconeogenesis as glycolysis and gluconeogenesis are reciprocally regulated
and highly depend on the availability of gluconeogenic substrates [1, 49]. The levels of glucose-
6-phosphate (G6P), a strong allosteric activator of GS [50], were 2.3-fold (p< 0.0001) higher
in the livers of Oct1-/- mice (Fig 4B). In addition, the ratio of phosphorylated GS to total GS
was significantly lower in Oct1-/- mice (Fig 4C), consistent with a higher activity of GS in
Oct1-/- mice. To further investigate the role of OCT1 in hepatic glucose metabolism, we per-
formed three standard tests related to glucose homeostasis [51]. In the glucose tolerance test
(GTT), the blood glucose rose following oral glucose dosing and fell back to normal in both
Oct1+/+ and Oct1-/- mice (S4D Fig), although the Oct1-/- mice had higher blood glucose levels at
baseline. After adjusting for baseline, there was a trend toward higher blood glucose levels and
an overall greater glucose AUC after a bolus dose of glucose in Oct1-/- mice (Fig 4D). The GTT
indicated that both Oct1+/+ and Oct1-/- mice could produce insulin in response to rising glu-
cose. In contrast, pyruvate tolerance tests (PTTs) were different between Oct1+/+ and Oct1-/-
mice (Fig 4E and S4E Fig). In particular, blood glucose was significantly higher at each time
point after pyruvate injection in Oct1-/- mice, which suggested that Oct1-/- mice had higher
rates of hepatic gluconeogenesis. In the insulin tolerance test (ITT), there was a trend toward
higher blood glucose levels after insulin injection in the Oct1-/- mice and an overall greater glu-
cose AUC (Fig 4F). Blood glucose levels are maintained by glucose uptake mainly in peripheral
tissues and glucose output primarily from the liver [52]. Data from the PTT suggested that the
knockout mice had significantly higher hepatic gluconeogenesis, which may have contributed
to the higher glucose exposure in Oct1-/- mice following the ITT.
Thiamine deficiency impaired glucose metabolism
To understand the role of thiamine in regulating glucose metabolism, age-matched mice were
placed on dietary chow containing three different doses of added thiamine, following the
experimental design shown in Fig 5A. Wild-type mice fed a TD for 10 days had higher levels of
hepatic glycogen, hepatic glucose, and plasma glucose compared to mice fed control diets (Fig
5B–5D). In contrast, varying thiamine content in the diet resulted in no significant differences
in hepatic glycogen, hepatic glucose, or plasma glucose levels among Oct1-/- mice (Fig 5B–5D).
Furthermore, wild-type mice fed TDs had similar levels of hepatic glycogen, hepatic glucose,
and plasma glucose as Oct1-/- mice irrespective of the thiamine content in their diets, consis-
tent with the idea that Oct1 deficiency mimics thiamine deficiency in wild-type mice. Levels of
G6P, an activator of GS, were significantly higher in livers from wild-type mice fed a TD diet
and were comparable to liver levels of G6P in Oct1-/- mice irrespective of thiamine content in
the diet (Fig 5E). As shown by western blotting (Fig 5F), livers from Oct1-/- mice in the control
thiamine diet group and from both Oct1+/+ mice and Oct1-/- mice in the TD group had higher
GS and Glut2 protein levels compared to Oct1+/+ mice in the thiamine control group. Taken
together, our data suggest that thiamine deficiency impairs glucose metabolism in wild-type
mice and that Oct1 deficiency phenocopies thiamine deficiency in wild-type mice.
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Oct1-/- mice had higher adiposity and altered lipid metabolism
Oct1-/- mice exhibited increased adiposity (Fig 2C and 2D), and examination of fat cells
through staining revealed significantly larger adipose cells in the epididymal fat pad (epididy-
mal white adipose tissue [eWAT], p = 0.004) and a trend toward larger adipose cells in retro-
peritoneal adipose tissue (rpWAT) from Oct1-/- mice (Fig 6A). To probe the mechanism of
increasing adiposity and adipose cell size in the Oct1-/- mice, we measured the mRNA expres-
sion levels of genes related to adipose metabolism. Fat gain may be due to imbalances between
rates of TG synthesis and lipolysis. The mRNA expression of patatin-like phospholipase
domain-containing protein 2 (Pnpla2) and lipase, hormone sensitive (Lipe) involved in adi-
pose lipolysis was reduced in adipose tissue from Oct1-/- mice compared to adipose tissue from
Oct1+/+ mice (Fig 6B). In contrast, levels of genes involved in TG synthesis were similar
between the two strains of mice (S5A Fig). Pnpla2 (coding for adipose triglyceride lipase
[ATGL]), Lipe (coding for hormone sensitive lipase [HSL]), and Mgll (coding for monoglycer-
ide lipase [MGLL]) are responsible for three major steps in mobilizing fat through hydrolysis
of TGs to release free fatty acids from the adipocytes [53]. Lower expression levels of these
genes are consistent with lower rates of lipolysis in adipose tissue from Oct1-/- mice. Insulin
has antilipolytic effects in adipose tissue, regulating ATGL expression and promoting lipid
synthesis, and chronic insulin treatment results in increased adipose mass [54, 55]. Corre-
sponding to the higher levels of glucose (Fig 6C), we observed higher circulating levels of
Fig 5. Different thiamine treatments affected glucose metabolism. (A) Scheme of experimental design. Two groups
of mice (Group-1 and Group-2) were treated with a CD, 5 mg/kg, and one group (Group-3) with an HT, 50 mg/kg, to
the end of the experiment. The third group of mice (Group-2) was treated with a CD but switched to a TD, 0 mg/kg,
for 10 days. After dietary treatment, mice were fasted overnight for 16 hours before being humanely killed (n = 4 per
genotype in each treatment). (B) Hepatic glycogen content quantification. (C) Hepatic glucose content quantification.
(D) Plasma glucose quantification. For (B–D), CD, TD, and HT indicate diet received by the mice during the final 10
days of treatment. (E) Hepatic glucose-6-phosphate content quantification. (F) Representative western blots of protein
expression in enzymes involved in energy metabolism; protein was pooled from 4 mice per genotype. Data shown are
mean ± SEM. Data were analyzed by ordinary one-way ANOVA and p-value is stated, and Dunnett’s post hoc test was
used to compare to the control (CD) group for (B), (C), and (D). Data were analyzed by unpaired two-tailed Student t
test for (E); p< 0.05, p< 0.01, and p< 0.001. Underlying data are provided in S1 Data. CD, thiamine controlled
diet; Glut2, glucose transporter 2; GS, glycogen synthase; GS-p641, phospho-glycogen synthase at serine 641; HT, high
thiamine diet; Oct1, organic cation transporter 1; TD, thiamine deficient diet.
https://doi.org/10.1371/journal.pbio.2002907.g005
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insulin in the Oct1-/- mice (Fig 6D and S5B Fig), which suppressed lipolysis. Furthermore, fast-
ing free fatty acid levels were lower in the plasma of Oct1-/- mice (Fig 6E), which may reflect
the lower rates of lipolysis in adipose tissue [56]. Data in Oct1 knockout mice were corrobo-
rated by data from inbred strains of mice. In particular, Oct1mRNA levels in the liver inversely
associated with percent fat growth and fat mass among various strains of mice (S1 Table). In
addition, down-regulation of mitochondrial uncoupling protein 2 (Ucp2) was observed in
brown adipose in Oct1-/- mice (S5G Fig), which may associate with the reduced energy
expenditure.
Examination of total cholesterol, HDL cholesterol, LDL cholesterol, and TG in plasma sam-
ples revealed significant differences in the two strains of mice. Notably, Oct1-/- mice had higher
plasma levels of total cholesterol and LDL cholesterol compared to Oct1+/+ mice, without sig-
nificant differences in TG and HDL cholesterol (Fig 6F). The increase in LDL was due primar-
ily to smaller LDL particles (Fig 6G). We observed no differences in the transcript levels of
lipoprotein lipase (Lpl) and Ldlr in livers from Oct1+/+ mice and Oct1-/- mice. However, livers
from Oct1-/- mice had higher transcript levels of 3-hydroxy-3-methylglutaryl-CoA reductase
(Hmgcr), and Acyl-CoA: cholesterol acyltranferase 2 (Acat2) (S5E Fig). Consistent with lower
activity of PDH, pyruvate levels were significantly higher in the livers from Oct1-/- mice, as less
pyruvate was converted to acetyl-CoA. Interestingly, contrary to our expectation, Oct1-/- mice
had higher levels of acetyl-CoA in their livers (Fig 6H and 6I). The higher accumulated acetyl-
CoA may have resulted from higher fatty acid β-oxidation in Oct1-/- mice [17, 48]. Our data
suggest that up-regulation of enzymes involved in cholesterol synthesis and higher levels of the
substrate precursor, acetyl-CoA, in the liver of Oct1-/- mice result in alterations in hepatic cho-
lesterol metabolism, leading to increased production of LDL particles. Furthermore, lower thi-
amine levels were correlated with higher levels of cholesterol in plasma and liver in male mice
from various inbred strains of mice (S2 Table and S6 Fig).
Discussion
Through extensive characterization of Oct1 knockout mice, our data provide compelling evi-
dence that Oct1 deficiency leads to a constellation of diverse effects on energy metabolism that
are consistent with GWAS demonstrating strong associations between OCT1 polymorphisms
and a variety of metabolic traits in humans (Fig 1 and Table 1). Our data support the notion
that hepatic thiamine deficiency is the underlying mechanism for the phenotypes associated
with reduced OCT1 function. Five major effects of OCT1 deficiency emerge from the current
study: (1) a shift in the pathway of energy production from glucose to fatty acid oxidation due
to lower activity of key thiamine-dependent enzymes in the liver; (2) increased gluconeogene-
sis and hepatic glucose output, with associated increases in liver glycogen and glucose levels;
Fig 6. Deletion of Oct1modulated lipid metabolism. (A) H&E staining of adipose tissues and adipose cell size quantification (n = 3 per genotype). (B)
mRNA expression of Pnpla2, Lipe, and Mgll in epididymal fat pads of mice fasted for 5 hours (n = 5 per genotype). (C) Blood glucose levels (n = 6 per
genotype). (D) Plasma insulin levels (n = 9 or 10 per genotype in 5-hour fasted group; n = 4 per genotype in 16-hour fasted group). (E) Plasma free fatty
acids levels in mice fasted for 5 hours (n = 9 or 10 per genotype). (F) Lipid panel showing plasma lipid levels in mice fasted for 5 hours (n = 9 or 10 per
genotype). (G) Fractionation of the lipoprotein particles by size (n = 9 or 10 per genotype). (H) Hepatic pyruvate levels (n = 4 per genotype in 5-hour
fasted group; n = 6 per genotype in 16-hour fasted group). (I) Hepatic acetyl-CoA levels (n = 4 per genotype in 5-hour fasted group; n = 6 per genotype in
16-hour fasted group). Data shown are mean ± SEM. Data were analyzed by unpaired two-tailed Student t test; p< 0.05, p< 0.01, and p< 0.001.
Underlying data are provided in S1 Data. (J) Scheme of overall mechanism. The scheme illustrates how OCT1 deficiency affects disposition of thiamine
and hence triggers a constellation of effects on hepatic and overall energy homeostasis. α-KGDH, α-ketoglutarate dehydrogenase; CHOL, cholesterol;
CoA, coenzyme A; eWAT, epididimal white adipose tissue; Glut2, glucose transporter 2; HDL-C, High-density lipoprotein cholesterol; H&E,
Haemotoxylin and Eosin; LDL-C, Low-density lipoprotein cholesterol; Lipe, lipase, hormone sensitive; Mgll, monoglyceride lipase; Oct1, organic cation
transporter 1; p-ACC, phosphorylated acetyl co-A; p-AMPK, phosphorylated 5’ adenosine monophosphate-activated protein kinase; PDH, pyruvate
dehydrogenase; Pnpla2, patatin-like phospholipase domain-containing protein 2; rpWAT, retroperitoneal adipose tissue; TCA, tricarboxylic acid; TPP,
thiamine pyrophosphate; TRIG, triglyceride.
https://doi.org/10.1371/journal.pbio.2002907.g006
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(3) increased peripheral adiposity stemming from alterations in energy metabolism; (4)
changes in hepatic cholesterol homeostasis and plasma lipids that may contribute to cardiovas-
cular disease risk; and (5) beneficial effects on life-threatening thiamine deficiency syndromes.
As the major energy-generating organ, the liver has high metabolic flexibility in selecting
different substrates to use in energy production in response to various metabolic conditions.
The glucose–fatty acid cycle, first proposed by Randle in 1963, plays a key role in regulating
metabolic fuel selection, and impairment in metabolic flexibility contributes to insulin resis-
tance and metabolic syndrome [17, 18, 47, 57, 58]. Many studies have shown that there is a fail-
ure to shift from fatty acid to glucose oxidation during the transition from fasting to feeding in
individuals with obesity or diabetes [48, 57]. We observed lower hepatic steatosis (Fig 2A),
largely due to increases in fatty acid oxidation in the liver [1, 59, 60]. Importantly, the observa-
tion that the Oct1-/- mice had significantly lower RERs during the dark cycle than their wild-
type counterparts suggests that overall, Oct1-/- mice have a greater reliance on energy produc-
tion from fatty acids over glucose during feeding than wild-type mice [61, 62] (S2J Fig). PDH
is the key enzyme switch for the glucose–fatty acid cycle [17, 63]. Thus, alterations in its activ-
ity by reduced levels of the cofactor TPP in Oct1-/- mice (Fig 4A) disrupt the hepatic glucose–
fatty acid cycle, resulting in an impairment of hepatic energy homeostasis. In livers from Oct1
deficient mice, β-oxidation of fatty acids becomes a major source of energy production, lead-
ing to impaired homeostasis in both lipid and carbohydrate metabolism.
In both the current study and our previous study [14], we observed increased levels of phos-
phorylated 50 adenosine monophosphate-activated protein kinase (AMPK)and its downstream
target, acetyl-CoA carboxylase (ACC), in livers from Oct1-/- mice compared to livers from
wild-type mice, indicative of a lower hepatic energy status in the knockout mice. As a result,
fatty acid β-oxidation was stimulated in the livers from Oct1-/- mice. However, as was evident
by lower hepatic ATP content, the increased rates of fatty acid oxidation were not sufficient to
compensate for normal rates of ATP production. Reduced glucose oxidation as well as a reduc-
tion in flux through the TCA cycle due to reduced activity of α-KGDH, another TPP-associ-
ated enzyme, may have contributed to the lower ATP production. Consistent with a lower flux
through the TCA cycle as well as increases in β-oxidation of fatty acids, we observed higher lev-
els of acetyl-CoA in livers from Oct1-/- mice. Studies have shown that acetyl-CoA allosterically
inhibits PDH, which results in further inhibition of glucose utilization [48, 58, 63]. Thus, in
the livers from Oct1-/- mice, this loop continued to stimulate fatty acid β-oxidation, which fur-
ther suppressed hepatic glucose utilization, shifting the major energy source from glucose to
fatty acids.
Increases in hepatic glycogen and glucose content in the Oct1-/- mice (Fig 2A, Fig 5B and
5C) were likely due to changes in intermediary metabolites resulting directly from alterations
in the activity of the TPP-dependent enzyme, PDH (Fig 4A). Reduced PDH activity resulted in
higher levels of pyruvate in the liver of Oct1-/- mice (Fig 6H), which is consistent with results
from previous studies [63, 64]. Higher pyruvate levels can drive hepatic gluconeogenesis,
resulting in increased hepatic glucose production and associated increases in hepatic glucose
and glycogen levels [1, 52]. Whereas our data suggested that the glycogen accumulation in the
livers of Oct1-/- mice resulted from changes in key intermediate metabolites that are involved
in hepatic energy metabolism, other regulatory paths such as hormonal, transcriptional, and
neural regulation need to be further studied.
Oct1-/- mice exhibited increased adiposity (Fig 2), which was more likely due to down-
stream effects of reduced transporter expression in the liver rather than in extra-hepatic tis-
sues. Multiple factors contributed to the increased adiposity, such as hyperinsulinemia,
hyperglycemia, increased hepatic glycogen, and reduced energy expenditure. Consistent with
the increased adiposity observed in the Oct1-/- mice, hepatic expression levels of Oct1 are
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inversely correlated with fat growth and fat mass in inbred strains of mice (S1 Table). In addi-
tion, hyperinsulinemia in Oct1 knockout mice may further result in increasing storage of TGs
and suppression of lipolysis in peripheral adipose tissue, which reduced flux of fatty acids to
the liver. Chronic insulin treatment has been shown to result in increased adipose mass due to
suppression of lipolysis and increased lipid storage [54, 55], and in the current study, a high
correlation between plasma insulin levels and fat mass in both wild-type and Oct1-/- mice (S5D
Fig) was observed. Furthermore, high insulin levels have been associated with low expression
levels of the lipolytic enzyme Pnpla2 in adipose tissue [55], consistent with results in the Oct1-/-
mice (Fig 6B), which is in agreement with the increased adiposity in these mice. In addition,
high hepatic glycogen levels may have contributed to the increased adiposity. In particular,
hepatic glycogen levels regulate the activation of the liver–brain–adipose axis [65]. Glycogen
shortage during fasting triggers liver–brain–adipose neurocircuitry that results in stimulation
of fat utilization. In contrast, in mice with elevated liver glycogen resulting from overexpres-
sion of GS or knockdown of PYGL, the liver–brain–adipose axis action is turned off, which
preserves fat mass [65]. The greater stores of glycogen in the livers of Oct1-/- mice may have
shut off the liver–brain–adipose axis, contributing to the increased peripheral adiposity in the
mice. Overall, our data in Oct1-/- mice suggest that OCT1 plays a key role in regulation of
peripheral metabolism, likely because of its effects on circulating glucose and insulin as well as
increased stores of hepatic glycogen triggering a feedback loop mechanism between the liver,
the brain, and the adipose tissue.
Parallels between phenotypes observed in GWAS in humans and those in the Oct1-/- mice
were striking. High plasma LDL, total cholesterol, and TG levels were observed in individuals
with reduced-function polymorphisms of OCT1 (R61C, F160L, G401S, V408M, 420del, and
G465R) (Table 1) as well as in the Oct1-/- mice (Fig 6F and 6G). In particular, the Oct1-/- mice,
and humans with reduced-function polymorphisms of OCT1 (S3 Table) [37], have increased
levels of small dense LDL particles (Fig 6G), which in humans are predictive of increased risk
of cardiovascular disease [66] and are a characteristic feature of the dyslipidemia associated
with excess adiposity [67] and insulin resistance [68]. We speculate that the increased LDL lev-
els in Oct1-/- mice may result from a relative deficiency of hepatic thiamine. Specifically, livers
from rats with thiamine deficiency have been shown to have lower TG but higher cholesterol
content [69], consistent with our data in inbred strains of mice, in which inverse correlations
were observed between plasma thiamine and cholesterol levels in both plasma and liver (S2
Table and S6 Fig). Importantly, our in vivo studies in mice showed that reduction of liver
Slc22a1 expression levels resulted in higher systemic thiamine levels (Fig 3B and 3E). Further-
more, individual OCT1 polymorphisms were nominally associated with systemic plasma levels
of thiamine in humans (S4 Table) [70] as well as when combining six of the OCT1 nonsynon-
ymous variants that were genotyped in the cohort by Rhee and colleagues (see S5 Table) [71].
Published studies in animals and humans suggest that thiamine supplementation may improve
blood lipid profiles [24, 25]. Higher levels of the precursor for cholesterol synthesis, acetyl-
CoA, as well as higher expression levels of enzymes involved in cholesterol synthesis [59, 72]
(S5E Fig), potentially leading to greater rates of hepatic cholesterol production, could have
contributed to the higher cholesterol and LDL levels in plasma. Although we were unable to
detect differences in total hepatic cholesterol content between Oct1+/+ mice and Oct1-/- mice
(S5F Fig) corresponding to the observed differences in plasma cholesterol levels between the
mouse strains, many factors that can modulate hepatic cholesterol content [73, 74], including
perhaps increased export, need further investigation. Further studies are warranted to investi-
gate the mechanisms underlying the effects of reduced OCT1 function as well as thiamine bio-
availability on cholesterol and lipoprotein metabolism.
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In addition to the metabolic changes that were observed in Oct1-/- mice, the knockout mice
were found to survive substantially longer on TDs. This may have been due to the higher sys-
temic levels of thiamine (Fig 3B), which would spare essential organs such as the brain and
heart from thiamine deficiency, as well as to the increased adiposity in the knockout mice (Fig
2C), which could protect the mice from the starvation that ensues from thiamine deficiency
[42, 75, 76]. Nevertheless, the results have implications for human ancestors who harbored
reduced-function genetic polymorphisms of OCT1. Because of differences in the tissue distri-
bution of OCT1 between humans and mice, our study has limitations in directly extrapolating
all the results obtained in mice to humans. In particular, because Oct1 is also abundantly
expressed in the kidney of mice, OCT1-mediated renal secretion of thiamine is another impor-
tant determinant of systemic thiamine levels in mice. In contrast, in humans, OCT1 plays a
role in modulating thiamine disposition largely in the liver and not in the kidney. Deletion of
Oct1, particularly in the kidney of the knockout mice, therefore, may have modulated systemic
thiamine levels and, thus, survival during TDs as well as other phenotypes observed in the cur-
rent study. Today, thiamine deficiency is associated with aging, diabetes, alcoholism, and poor
nutritional status [23, 77–79]. In the setting of thiamine deficiency, OCT1 reduced-function
polymorphisms today would have mixed effects. On the one hand, individuals who harbored
reduced-function variants would have higher systemic levels of thiamine, which may protect
essential organs from thiamine depletion. On the other hand, the individuals would have low
hepatic thiamine levels, which may predispose them to the deleterious effects of dysregulated
plasma lipids and to obesity and diabetes (Table 1). In fact, lower thiamine levels have been
reported in individuals with diabetes [23, 78] and, as noted, some studies have shown that
high-dose thiamine supplementation has beneficial effects on diabetes [25, 80, 81].
Overall, the current study shows that OCT1 deficiency triggers a constellation of effects on
hepatic and overall energy homeostasis (Scheme in Fig 6J). That is, reduced OCT1-mediated
thiamine uptake in the liver leads to reduced levels of TPP and a decreased activity of key TPP-
dependent enzymes, notably PDH and α-KGDH. As a result, there is a shift from glucose to
fatty acid oxidation, which leads to imbalances in key metabolic intermediates, notably, ele-
vated levels of pyruvate, G6P, and acetyl-CoA. Because of these imbalances, metabolic flux
pathways are altered, leading to increased gluconeogenesis and glycogen synthesis in the liver.
In addition, the increased acetyl-CoA levels along with elevated expression levels of key
enzymes involved in cholesterol synthesis likely contribute to increases in plasma levels of total
and LDL cholesterol observed in mice with Oct1 deficiency and in humans with reduced-func-
tion genetic polymorphisms of OCT1. Although many of the details of the mechanisms have
still to be worked out, our study provides critical insights into the role of thiamine in the liver
in maintaining metabolic balance among energy metabolism pathways. Finally, our studies
provide mechanistic insights into findings from GWAS implicating reduced-function variants
in the SLC22A1 locus as risk factors for lipid disorders and diabetes.
Materials and methods
Ethics statement
Animal experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) of University of California, San Francisco (AN119364), in accordance with the
requirements of the National Research Council Guide for the Care and Use of Laboratory Ani-
mals and the Public Health Service Policy on the Humane Care and Use of Laboratory Ani-
mals. Humane end points were determined by body condition score of 2 or less or 15% body
weight loss. Animals were euthanized once the humane end points were reached during the
treatment in accordance with IACUC approved protocol. To limit pain and stress, mice were
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anesthetized deeply by isoflurane vaporizer and intraperitoneal injection of ketamine/medeto-
midine cocktail (75/1 mg/kg) prior to the physical cervical dislocation of euthanasia.
Mining genetic association studies to identify phenotypes associated with
SLC22A1 reduced-function variants
Various publicly available databases were used to determine whether there are significant
genetic associations of SLC22A1 reduced-function variants with human diseases and traits.
The following databases were used: GWAS Catalog, dbGAP Association Results Browser,
GRASP: Genome-Wide Repository of Associations Between SNPs [82], GIANT Consortium,
Type 2 Diabetes Knowledge Portal, and Phenotypes and Genome Wide Associations Studies
for Lipid Genetics. The first three databases, GWAS Catalog, dbGAP Association Results
Browser, and GRASP, provide an easy to use interface to allow first-step information gathering
of the types of human diseases and traits that have been reported in all published GWAS.
Based on the results from the three databases, other specific databases relevant to the findings
were then used. This includes searching for specific databases that have the GWAS summary
statistics (beta coefficient and p-values). These are GIANT Consortium for body weight, Type
2 Diabetes Knowledge Portal for glucose and insulin traits, and all GWAS for lipid traits.
These databases allow investigators to download the association studies for obtaining the p-
values and the beta coefficients for the associations. In this study, we focused our search on
nonsynonymous variants of OCT1 (SLC22A1) with minor allele frequencies1% in popula-
tions with European ancestries (1000 Genome Project): R61C (rs12208357), F160L (rs683369),
P341L (rs2282143), G401S (rs34130495), M408V (rs628031), 420Del (rs202220802) (rs662138
and rs1564348, which are in linkage disequilibrium to 420Del with r2 0.77, D0 > 0.95), and
G465R (rs34059508).
Animal studies
All experiments on mice were approved by the IACUC of UCSF. Oct1-/- mice were generated as
previously described [83] and backcrossed more than 10 generations to FVB/N background.
Mice were housed in a pathogen-free facility with a 12-hour light and 12-hour dark cycle and
given free access to food and water. Five- or six-week-old experimental mice were fed with thia-
mine control diet Cat# TD.09549 (thiamine 5 mg/kg) containing 17.5% protein, 65.8% carbohy-
drate, and 5.0% fat by weight (Envigo, Madison, WI). Other thiamine diets contained the same
composition as the thiamine control diet but differed in thiamine levels (TD Cat# TD.81029, 0
mg/kg; adjusted thiamine diet with different thiamine doses added, Cat# TD.120472, 25 mg/kg;
Cat# TD.140164, 50 mg/kg). The periods of dietary treatments and time for mouse being
humanely killed are indicated in the Results section and figure legends. The animal studies were
conducted in male mice; however, overall body weight and liver weight were assessed in female
mice. Mice treated with TD developed thiamine deficiency syndromes, resulting in reduction of
food intake and body weight loss. During the treatment period, mice were closely monitored
and weighed daily. Animals were euthanized once the humane end points (body condition
score of 2 or less or 15% body weight loss) were reached during the treatment. To limit pain
and stress, mice were anesthetized deeply by isoflurane vaporizer and intraperitoneal injection
of ketamine/medetomidine cocktail (75/1 mg/kg) prior to the physical cervical dislocation of
euthanasia.
Hydrodynamic tail vein injection
Hydrodynamic tail vein injection procedure was conducted as described previously [84], with
minor modifications. Briefly, the body weights of the mice were used to calculate the total
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volume (mL) required for injection based on the formula: body weight (g)  (mL/10g) + 0.1
mL (dead volume). The injection solution included 510^7 TU virus/mouse and saline to just
the final volume. Instead of anesthetizing the mice, we used TransIT-QR kit MIR5210 (Mirus
Bio LLC, US) and followed the online protocol (https://www.mirusbio.com/delivery/tailvein/).
Dosing of 3H-thiamine was performed 48 hours after hydrodynamic tail vein injection. Mouse
Slc22A1 shRNA lentiviral particle (TRCN0000070156) and nonmammalian shRNA control
pLKO.1 (SHC002V) were purchased from Sigma. Viruses were verified in HEK-293 cells.
Briefly, pcDNA5 containing mouse Slc22a1was cotransfected with the Slc22a1 knockdown
vector or pLKO.1 control virus. mRNA was isolated after 48 hours transduction, and mRNA
expression of Oct1 was measured.
Body composition and metabolic cages
Before and during dietary treatment, body composition was determined by either quantitative
magnetic resonance on the EchoMRI-3in1 body composition analyzer (EchoMRI, Houston,
TX) or by DEXA. For DEXA, live animals were anesthetized with isoflurane and scanned on
the Lunar PIXImus densitometer (Lunar PIXImus Corporation Headquarters, Madison, WI).
After 8 weeks diet treatment, mice were placed in single housing cages for 3 days before initiat-
ing the CLAMS (Columbus Instruments, Columbus, OH) experiments. CLAMS was used to
monitor food and water intake, oxygen consumption (VO2) and carbon dioxide production
(VCO2), and locomotor activities for a period of 96 hours. All these experiments were per-
formed in the Diabetes and Endocrinology Research Center Mouse Metabolism Core at
UCSF.
In vivo studies
Blood glucose levels from mice were measured using the FreeStyle Freedom Lite blood glucose
meter (Abbott Laboratories, Chicago, IL) in samples obtained by the tail milking method. For
oral glucose tolerance tests (OGTTs), mice were fasted for 5 hours and dosed with glucose 2 g/
kg (Sigma-Aldrich, St. Louis, MO) by oral gavage. For ITTs, mice were fasted for 5 hours and
dosed with 0.75 U/kg humulin R insulin 100 U/ml (Henry Schein Animal Health, Dublin,
OH) by intraperitoneal injection. Blood was sampled at 0, 15, 30, 60, 90, and 120 minutes. For
PTTs, mice were fasted overnight for 16 hours and dosed with pyruvate 2 g/kg (Sigma-Aldrich,
St. Louis, MO) by intraperitoneal injection. Blood was sampled at 0, 15, 30, 60, 90, 120, 150,
and 180 minutes.
Tissue staining and histology
For adipose tissues and liver glycogen staining, mice were fasted for 16 hours and perfused
with 20 mL 4% paraformaldehyde (PFA) in PBS. Epididymal fat pad, rpWATs, and liver were
incubated in 4% PFA for 48 hours at 4˚C and transferred to 70% ethanol. For Oil Red-O
(ORO) staining in liver, mice were fasted for 16 hours and perfused with 10 mL PBS. Livers
were fixed via sucrose infiltration steps prior to freezing. After incubating in 30% sucrose in
PBS at 4˚C for 24 hours, tissues were frozen in OCT molds. Fixed or frozen tissues were trans-
ferred to the histology and light microscopy core at Gladstone Institutes for staining, imaging,
and analysis. For the cell-size analysis, hematoxylin and eosin-stained paraffin-embedded sec-
tions (https://labs.gladstone.org/histology/pages/section-staining-haematoxylin-and-eosin-
staining) of mouse adipose tissues were imaged using a Nikon Eclipse E600 upright micro-
scope equipped with a Retiga camera (QImaging, Vancouver, BC, Canada) and a Plan Fluor
20×/0.3NA objective. For each sample, four independent fields were imaged for analysis and
adipocyte size was determined using ImageJ (v.2.0.0-rc-3) software (US National Institutes of
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Health) and the Tissue Cell Geometry macro (http://adm.irbbarcelona.org/image-j-fiji). For
quantifying the lipid droplets, ORO stained frozen sections of mouse liver were imaged as
above. For each sample, four independent fields were imaged for analysis. RGB images were
then color thresholded to ORO, and the total area of ORO-positive pixels was summed for
each image using the Analyze Particles function. For quantifying the glycogen levels in liver
sections, Periodic-Acid Schiff’s stained mouse liver was imaged as above. For each sample,
four independent fields were imaged and the mean intensity and integrated density values
were averaged for each image using the Analyze Particles function.
Metabolic parameters measurements
Mice were humanely killed and blood was collected via posterior vena cava to BD microtainer
tubes with dipotassium EDTA (365974) or heparin (365985). Plasma was sent to the Clinical
Laboratory of San Francisco General Hospital for measurement of total, LDL, and HDL choles-
terol and TGs and liver panel. Plasma was send to Children’s Hospital Oakland Research Insti-
tute for the measurement of lipoprotein particles size, as described previously [85]. Glucose
(GAGO20), glycogen (MAK016), free fatty acid (MAK044), acetyl-Coenzyme A (MAK039),
and G6P (MAK014) quantification kits were purchase from Sigma-Aldrich (St. Louis, MO).
Pyruvate (ab65342), cholesterol (ab102515), and TG (ab65336) quantification kits were pur-
chase from Abcam (Cambridge, MA). Plasma insulin was measure by ELISA (EMINS) from
Thermo Fisher Scientific (Waltham, MA). Plasma was sent to Molecular MS Diagnostics, Inc.
(Warwick, RI), for thiamine quantification, as previously described [14].
Western blot analysis
Tissues were homogenized in CelLytic MT lysis buffer (Sigma-Aldrich, St. Louis, MO) with
cOmplete ULTRA protease inhibitor tablet and PhosSTOP phosphatase inhibitor tablet freshly
added (Roche). After normalization, equal protein amounts from each sample were loaded in to
4%–20% criterion Tris-HCl gel (Bio-Rad, Hercules, CA) and run at 110 V. Protein was trans-
ferred to EMD milllipore immobilon PVDF membranes at 100 V for 1 hour at 4˚C using the
criterion blotter. GS (15B1) (#3886; 1:1,000 dilution), phospho-glycogen synthase (Ser641)
(#3891, 1:1,000 dilution), phospho-acetyl-CoA carboxylase (Ser79) (#3661; 1:2,000 dilution),
AMPKα (23A3) (#2603, 1:1,000 dilution), and phospho-AMPKα (Thr172) (#2535; 1:1,500 dilu-
tion) were purchased from Cell Signaling Technology (Danvers, MA). Anti-PDH-E1α (pSer232)
(#AP1063; 1:2,000 dilution) and Anti-PDH-E1α (pSer300) (#AP1064; 1:2,000 dilution) were pur-
chased from EMD Millipore (Billerica, MA). PDH-E1α (D-6) (#sc-377092; 1:200 dilution) and
β-actin (C4) (#sc-47778; 1:4,000 dilution) were purchased from Santa Cruz Biotechnology, Inc.
(Dallas, TX). Anti-PYGL (#ab198268; 1:1,000 dilution) was purchased from Abcam (Cam-
bridge, MA). Anti-Glut2 (#600-401-GN3; 1:1,000 dilution) was purchased from Rockland (Lim-
erick, PA). Primary antibodies were incubated overnight at 4˚C. Secondary antibodies, goat
anti-rabbit IgG-HRP (#sc-2030; 1:5,000; Santa Cruz Biotechnology, Inc.), and anti-mouse
IgG-HRP (#7076; 1:5,000; Cell Signaling Technology) were incubated for 2 hours at room tem-
perature. Either Amersham ECL western blotting detection reagents (RPN2106) or ECL Prime
western blotting detection reagents (RPN2232) were used for detection. Membranes were
imaged by ProteinSimple western blot imaging system (San Jose, CA). For the quantification of
western blot bands, the ImageJ (US National Institutes of Health) method was used.
Gene expression analysis
Total RNA from mouse tissues or cell lines was isolated using RNeasy Mini kit (Qiagen, Valen-
cia, CA). Total RNA (2 μg) from each sample was reverse transcribed into cDNA using
Hepatic thiamine deficiency promotes metabolic disorders
PLOS Biology | https://doi.org/10.1371/journal.pbio.2002907 April 16, 2018 24 / 33
SuperScript VILO cDNA Synthesis kit (Life Technologies, CA). Quantitative real-time PCR
was carried out in 384-well reaction plates using 2X Taqman Fast Universal Master Mix
(Applied Biosystems, Foster City, CA), 20X Taqman specific gene expression probes, and 10
ng of the cDNA template. The reactions were carried out on an Applied Biosystems 7900HT
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The relative expression
level of each mRNA transcript was calculated by the comparative method (ΔΔCt method), nor-
malized to the housekeeping gene, β-actin.
Transporter uptake studies
The stably overexpressing pcDNA5 empty vector, mouse OCT1, human OCT1-reference,
OCT1-420 del, and OCT1-420 del+G465R cell lines were maintained in Dulbecco’s Modified
Eagle Medium (DMEM H-21) supplemented with hygromycin B (100 ug/mL) (Thermo Fisher
Scientific, Waltham, MA), penicillin (100 U/mL), streptomycin (100 mg/mL), and 10% fetal
bovine serum. Cell culture supplies were purchased from the Cell Culture Facility (UCSF,
CA). Cells were cultured on poly-D-lysine coated 96-well plates for 24 hours to reach 95% con-
fluence. Before the uptake experiments, the culture medium was removed and the cells were
incubated in Hank’s balanced salt solution (HBSS) (Life Technology, CA) for 15 minutes at
37˚C. Radiolabeled thiamine [3H(G)] hydrochloride (20 Ci/mmol) was purchased from Amer-
ican Radiolabeled Chemicals Incorporation (St. Louis, MO). Thiamine hydrochloride was pur-
chased from Sigma-Aldrich (St. Louis, MO). Chemicals and radiolabeled compounds were
diluted in the HBSS for uptake experiments. The details for drug concentrations and uptake
time are described in the Results section and figure legends. The uptake was performed at
37˚C, and then the cells were washed three times with ice-cold HBSS. After that, the cells were
lysed with buffer containing 0.1 N NaOH and 0.1% SDS, and the radioactivity in the lysate was
determined by liquid scintillation counting. For the transporter study, the Km and Vmax were
calculated by fitting the data to a Michaelis-Menten equation using GraphPad Prism software
6.0 (La Jolla, CA).
Statistical analysis
All mice were randomly assigned to the control or each treatment group. No statistical method
was used to predetermine sample size, and sample size was determined on the basis of previous
experiments. Numbers of mice for each experiment are indicated in figure legends. Mice that
were dead or sick before the end of experiments were excluded from the final analysis. Investi-
gators were not blinded during experiments. Data were expressed as mean ± SEM. Appropri-
ate statistical analyses were applied, as specified in the figure legends. Data were analyzed
using GraphPad Prism software 6.0 (La Jolla, CA). Differences were considered statistically sig-
nificant at p< 0.05; p< 0.05, p< 0.01, and p< 0.001.
Supporting information
S1 Fig. Manhattan plots of the meta-analysis genome-wide association of SNPs. (A) Man-
hattan plots of the meta-analysis genome-wide association of SNPs with LDL cholesterol levels
and (B) total cholesterol. The data are shown as −log10 p-value in up to 188,577 individuals
with European Ancestry. The data are plotted using the results available from the Global Lipids
Genetics Consortium, http://csg.sph.umich.edu/abecasis/public/lipids2013/. The names of the
genes in the top locus for each chromosome were labeled. Over 100 loci were associated with
lipids at p< 5 × 10−8, including SLC22A1, which is the top locus in chromosome 6. (C) The
plot shows the correlation, R2, among the SNPs in the SLC22A1, SLC22A2, SLC22A3, LPAL2,
and LPA genes. Darker red showed R2 > 0.8, whereas light color showed weak linkage. SNPs
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in SLC22A1 (on the top left region: rs12208357 [R61C], rs2282143 [P341L], rs683369, rs34130495
[G401S], rs628031 [V408M], rs662138 [LD to 420del], rs1443844, rs11753995, rs34059508
[G465R], rs2297374, rs1564348 [LD to 420del]) have very weak linkage, R2< 0.1, with SNPs
in LPAL2 and LPA genes region (bottom right region: rs3798220, rs7767084, rs10755578,
rs6415084, rs74617384, rs3798221, rs191555775, rs55730499, rs41272114, rs10455872, rs7770628,
rs9355814, rs7759633, rs1367211, rs1406888, rs2315065, rs186696265). One of the missense SNPs
in OCT1, rs2282143 (P341L), has a weak correlation, r2 = 0.54, with a missense variant Ile1891Met
(rs3798220). This plot was generated using LDLink, https://analysistools.nci.nih.gov/LDlink/?
tab=ldmatrix. The R2 information is generated using genotype data from 1000 Genomes popula-
tion from European Ancestry. G401S, Glycine to serine in amino acid position 401; G465R, Gly-
cine to Arginine in amino acid position 465; I1891M, Isoleucine to methionine in amino acid
position 1891; LD, linkage disequilibrium; LDL, low-density lipoprotein; LPA, lipoprotein(a);
LPAL2, lipoprotein(a) like 2; OCT1, organic cation transporter 1; P341L, Proline to Leucine in
amino acid position 341; R61C, Arginine to cysteine in amino acid position 61; SLC, solute carrier;
V408M, Valine to methionine in amino acid position 408; 420del, methinone420 deletion.
(DOCX)
S2 Fig. Altered energy metabolism in Oct1-/- mice. (A) Lipid droplet quantification of ORO
liver staining images (n = 3 per genotype). (B) Density quantification of PAS liver staining
images for glycogen (n = 3 per genotype). (C) Quantified hepatic glucose for mice fasted 16
hours overnight (n = 10 per genotype). (D) Body weights for mice fasted 16 hours (n = 14 per
genotype). (E) Percent of epididymal fat pad weight and liver weight to total body weight
(n = 14 per genotype). Similar trends in liver weight, but not body weight, were observed in
female mice (data not shown). (F) Respiratory O2 consumption normalized by lean body
weight for 96 hours and calculated AUC. (G) Energy expenditure normalized by lean body
weight for 96 hours and calculated AUC. (H) Activity counts for 96 hours, and associated sum-
mary of activity. (I) Food intake. (J) Respiratory exchange ratio, RER = VCO2/VO2 (n = 12 per
genotype). (K) Liver function test (n = 5 per genotype). (L) mRNA expression levels for thia-
mine transporters in the liver (n = 6 per genotype). Data shown are mean ± SEM. Data were
analyzed by unpaired two-tailed Student t test; p< 0.05, p< 0.01, and p< 0.001. Under-
lying data are provided in S1 Data. AUC, area under the curve; Oct1, organic cation trans-
porter 1; ORO, Oil Red-O; O2, oxygen; PAS, Periodic Acid-Schiff; VCO2, carbon dioxide
production; VO2, oxygen consumption.
(DOCX)
S3 Fig. Effects of OCT1 and its genetic variants on thiamine disposition. (A) Plasma thia-
mine concentration (n = 6 per genotype in each diet). (B) Thiamine uptake in cells expressing
EV and hOCT1-Ref. n = 3 replicated wells; two separate experiments performed for in vitro
studies. (C) Oct1mRNA expression levels in cells stably expressing EV, hOCT1-Ref, hOCT1-
420Del, and hOCT1-420Del+G465R (n = 3 wells per cell line). (D) Mouse Slc22A1 shRNA len-
tiviral particle knockdown experiments in mouse OCT1 overexpressing cells and wild-type
mice. Data show mRNA levels in the livers and kidneys of control mice and mice that received
a hydrodynamic tail vein injection of shRNA to OCT1. The maximal plasma concentration of
thiamine. A single intraperitoneal injection of 2 mg/kg thiamine (with 4% 3H-thiamine) was
administered to four groups of mice (Oct1+/+ mice treated with control shRNA, n = 6; Oct1+/+
mice treated with Oct1 shRNA, n = 6; Oct1-/- mice treated with control shRNA, n = 3; and
Oct1-/- mice treated with Oct1 shRNA, n = 3) Data are normalized to Oct1+/+ mice treated with
control shRNA. Data shown are mean ± SEM. Data were analyzed by unpaired two-tailed Stu-
dent t test; p< 0.05, p< 0.01, and p< 0.001. Underlying data are provided in S1 Data.
EV, empty vector; hOCT1-Ref, human OCT1 reference; hOCT1-420Del, human OCT1 with
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methinone420 deletion; hOCT1-420Del+G465R, human OCT1 with mutation in glycine465-to-
arginine in addition to 420Del; OCT1, organic cation transporter 1; shRNA, short hairpin
RNA; Slc, solute carrier.
(DOCX)
S4 Fig. Deletion of oct1 altered hepatic glucose metabolism. (A) Pdk4 mRNA expression.
(B) Slc2a2mRNA expression (n = 10 per genotype in mice fasted 16 hours; n = 6 per genotype
in mice fasted 5 hours). (C) Ratio of GS to PYGL in protein expression (n = 8 mice per geno-
type). (D) GTT in mice fasted 5 hours (n = 10 per genotype). (E) PTT in mice fasted 16 hours
(n = 6 per genotype). Data shown are mean ± SEM. Data were analyzed by unpaired two-tailed
Student t test; p< 0.05, p< 0.01, and p< 0.001. Underlying data are provided in S1
Data. GS, glycogen synthase; GTT, glucose tolerance test; oct1, organic cation transporter 1;
Pdk4, pyruvate dehydrogenase kinase 4; PTT, pyruvate tolerance test; PYGL, glycogen phos-
phorylase; Slc, solute carrier.
(DOCX)
S5 Fig. Deletion of Oct1 affected lipid metabolism. (A) mRNA expression of genes involved
in energy metabolism in epididymal fat pads in mice fasted 5 hours (n = 5 per genotype). (B)
Correlation between blood glucose and plasma insulin levels. (C) Correlation between plasma
insulin and plasma free fatty acid levels. (D) Correlation between plasma insulin levels and epi-
didymal fat pad mass. (E) mRNA expression of genes involved in cholesterol metabolism in
mouse livers fasted 5 hours (n = 5 per genotype). (F) Hepatic total cholesterol content. (G)
mRNA expression levels of genes involved in energy metabolism in brown adipose tissue. Data
shown are mean ± SEM. Data were analyzed by unpaired two-tailed Student t test; p< 0.05,
p< 0.01, and p< 0.001. Underlying data are provided in S1 Data. Oct1, organic cation
transporter 1.
(DOCX)
S6 Fig. Correlation of plasma thiamine levels with plasma lipid traits in inbred strains of
mice. The data were obtained from previous studies conducted by the Aldon J. Lusis labora-
tory. (A) Correlation between plasma levels of thiamine and plasma LDL. (B) Correlation
between plasma thiamine levels and plasma unesterified cholesterol. (C) Correlation between
plasma thiamine levels and plasma esterified cholesterol. (D) Correlation between plasma thia-
mine levels and plasma total cholesterol. The figures were plotted using Pearson and Spearman
correlation. Underlying data are provided in S1 Data. LDL, low-density lipoprotein.
(DOCX)
S1 Table. Summary of association results for liver Slc22a1 mRNA expression with relevant
traits among inbred strains of mice. Slc, solute carrier.
(DOCX)
S2 Table. Summary of association results for plasma thiamine with relevant traits among
inbred strains of mice.
(DOCX)
S3 Table. Association of OCT1 missense variants with circulating metabolites related to
lipid particles. OCT1, organic cation transporter 1.
(XLSX)
S4 Table. Associations of SLC22A1 reduced-function nonsynonymous variants (R61C,
G401S, V408M, G465R) with thiamine levels in human. G401S, Glycine to serine in amino
acid position 401; G465R, Glycine to arginine in amino acid position 465; R61C, Arginine to
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cysteine in amino acid position 61; SLC, solute carrier; V408M, Valine to methionine in
amino acid position 408.
(XLSX)
S5 Table. Associations of six SLC22A1 nonsynonymous variants (R61C, C88R, F160L,
G401S, V408M, G465R) with thiamine levels in human. C88R, Cysteine to arginine in
amino acid position 88; F160L, Phenylalanine to leucine in amino acid position 160; G401S,
Glycine to serine in amino acid position 401; G465R, Glycine to Arginine in amino acid posi-
tion 465; R61C, Arginine to cysteine in amino acid position 61; SLC, solute carrier; V408M,
Valine to methionine in amino acid position 408.
(XLSX)
S1 Data. Contains underlying data for figures.
(XLSX)
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